Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced Cardiotoxicity
Abstract Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. R...
Saved in:
| Published in: | Clinical colorectal cancer Vol. 12; no. 1; pp. 8 - 14 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01-03-2013
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Abstract Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because it carries a high risk of recurrence of the cardiac symptoms and prophylactic treatment is not always protective. Possible alternative treatment options to be considered are to replace the oral capecitabine or intravenous 5-FU by a 5-FU bolus regimen, by uracil-tegafur or tegafur/gimeracil/oteracil, both oral fluoropyrimidines combining a 5-FU prodrug with a dihydropyrimidine dehydrogenase (DPD) inhibitor, or by raltitrexed, a thymidilate synthase inhibitor whose metabolism is independent of DPD. Patients with advanced colorectal cancer and fluoropyrimidine-induced cardiotoxicity can be treated with other non-fluoropyrimidine related chemotherapy, either as a single agent, combined, or in combination with biological agents. In this report we discuss the different alternative treatment options. |
|---|---|
| AbstractList | Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because it carries a high risk of recurrence of the cardiac symptoms and prophylactic treatment is not always protective. Possible alternative treatment options to be considered are to replace the oral capecitabine or intravenous 5-FU by a 5-FU bolus regimen, by uracil-tegafur or tegafur/gimeracil/oteracil, both oral fluoropyrimidines combining a 5-FU prodrug with a dihydropyrimidine dehydrogenase (DPD) inhibitor, or by raltitrexed, a thymidilate synthase inhibitor whose metabolism is independent of DPD. Patients with advanced colorectal cancer and fluoropyrimidine-induced cardiotoxicity can be treated with other non-fluoropyrimidine related chemotherapy, either as a single agent, combined, or in combination with biological agents. In this report we discuss the different alternative treatment options. Abstract Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because it carries a high risk of recurrence of the cardiac symptoms and prophylactic treatment is not always protective. Possible alternative treatment options to be considered are to replace the oral capecitabine or intravenous 5-FU by a 5-FU bolus regimen, by uracil-tegafur or tegafur/gimeracil/oteracil, both oral fluoropyrimidines combining a 5-FU prodrug with a dihydropyrimidine dehydrogenase (DPD) inhibitor, or by raltitrexed, a thymidilate synthase inhibitor whose metabolism is independent of DPD. Patients with advanced colorectal cancer and fluoropyrimidine-induced cardiotoxicity can be treated with other non-fluoropyrimidine related chemotherapy, either as a single agent, combined, or in combination with biological agents. In this report we discuss the different alternative treatment options. |
| Author | Deboever, Guido Hiltrop, Nick Lambrecht, Guy Cool, Mike |
| Author_xml | – sequence: 1 fullname: Deboever, Guido – sequence: 2 fullname: Hiltrop, Nick – sequence: 3 fullname: Cool, Mike – sequence: 4 fullname: Lambrecht, Guy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23102544$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcuKFDEUhoOMOBd9AReSF6gyl0pVB0QYGmccGBjBEZchl1OYNp00SXqY3vkO84Y-iSlaXbhwlUPyf4eT75yjk5giIPSakp4SOr7d9DZY2zNCWU9kTwh_hs6o5KuOjNNw0mrBeUcIW52i81I2rRo5pS_QKeOUMDEMZ-hwGSrkqKt_AHyfQdctxIrvdtWnWLCPeJ1CymCrDnito4WMP7V0CxX81ddvWPz88XQV9imnfdbWhw6n3JI7sL5q4yN0N9HtLbh2mZ1PNT369nR4iZ7POhR49fu8QF-uPtyvP3a3d9c368vbzg5C1M4ZPs5yNsbJyUlNyUCls9NAHNjBGAZCM7li0o4jzIKJaWXEpLl0wphRipFfIHbsa3MqJcOsdtlvdT4oStTiUW3U4lEtHhWRqnls0JsjtNubLbi_yB9xLfDuGIA2-oOHrIptUto3_SJLueT_3__9P7gNPnqrw3c4QNk0l7FJUVSVxqjPyyaXRVJGCKVk4r8A16-dtg |
| CitedBy_id | crossref_primary_10_1016_j_prp_2024_155457 crossref_primary_10_1080_0284186X_2019_1711164 crossref_primary_10_1016_j_clcc_2015_02_005 crossref_primary_10_1016_j_repc_2017_04_010 crossref_primary_10_2217_fon_2016_0109 crossref_primary_10_3389_fcvm_2021_721107 crossref_primary_10_1016_j_critrevonc_2018_03_014 crossref_primary_10_3233_JIFS_179402 crossref_primary_10_1002_ehf2_14879 crossref_primary_10_1080_01635581_2020_1804948 crossref_primary_10_5306_wjco_v11_i12_1008 crossref_primary_10_2340_1651_226X_2024_24023 crossref_primary_10_17816_22217185_2021_3_201098 crossref_primary_10_20515_otd_986616 crossref_primary_10_7759_cureus_17712 crossref_primary_10_1016_j_repce_2017_04_015 crossref_primary_10_3390_ph14060563 crossref_primary_10_1007_s13277_015_4676_4 crossref_primary_10_1038_s41419_020_03266_3 crossref_primary_10_1007_s13402_014_0214_4 crossref_primary_10_1016_j_critrevonc_2018_02_002 crossref_primary_10_3892_or_2022_8468 crossref_primary_10_1055_s_0043_1778685 crossref_primary_10_1016_j_esmoop_2022_100427 crossref_primary_10_1188_14_CJON_360_362 crossref_primary_10_1016_j_ctrv_2021_102218 crossref_primary_10_1186_s12885_016_2409_8 crossref_primary_10_1016_j_scitotenv_2015_04_111 crossref_primary_10_1186_s40880_018_0292_1 crossref_primary_10_1016_j_dld_2021_08_009 crossref_primary_10_3389_fcvm_2022_960240 crossref_primary_10_3892_mco_2017_1436 crossref_primary_10_1007_s12170_017_0558_1 crossref_primary_10_1159_000443984 crossref_primary_10_12998_wjcc_v7_i1_89 crossref_primary_10_1016_j_bbamcr_2024_119684 crossref_primary_10_1080_10643389_2017_1370990 crossref_primary_10_1097_CAD_0000000000000891 crossref_primary_10_1016_j_jaccao_2021_11_001 crossref_primary_10_3892_mmr_2014_2438 crossref_primary_10_1016_j_canrad_2020_06_029 crossref_primary_10_1016_j_esmoop_2023_101199 crossref_primary_10_1016_j_clcc_2018_09_010 crossref_primary_10_1016_j_ejmech_2015_09_036 crossref_primary_10_1093_annonc_mdu055 crossref_primary_10_2147_CMAR_S273544 crossref_primary_10_1136_bcr_2016_219162 |
| Cites_doi | 10.1007/s00280-003-0617-9 10.1016/j.ejca.2005.03.027 10.1093/annonc/mdh150 10.1038/sj.bjc.6600781 10.1038/sj.bjc.6600967 10.1093/annonc/mdf108 10.1200/JCO.1992.10.11.1795 10.2174/187152506775268785 10.1191/0960327106ht628oa 10.1016/S1470-2045(10)70181-9 10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E 10.1038/bjc.1998.12 10.1093/annonc/mdg254 10.1159/000227226 10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C 10.1016/j.ejca.2008.07.002 10.1023/A:1011194712661 10.1056/NEJM200009283431302 10.1016/j.ejca.2010.09.022 10.1097/00000441-198710000-00004 10.1007/s00280-011-1669-x 10.1253/jcj.59.303 10.1016/0002-8703(87)90517-5 10.1056/NEJMoa071834 10.1002/jps.2600730217 10.1093/annonc/mdf229 10.1111/j.1445-5994.2009.02144.x 10.1097/CAD.0b013e32833c57cf 10.1517/14740330902733961 10.1038/sj.bjc.6602860 10.1200/JCO.2003.08.058 10.1200/JCO.2007.14.9898 10.1254/jjp.30.871 10.1177/030089168206800609 10.1038/sj.bjc.6602462 10.1200/jco.2011.29.15_suppl.3524 10.3816/CCC.2002.n.010 10.1080/07357900701518388 10.1038/sj.bjc.6601224 10.1200/JCO.2002.04.123 10.3816/CCC.2009.n.009 10.1056/NEJMoa033025 10.1517/17425247.2012.652945 10.1200/JCO.2005.04.7498 10.1200/JCO.2009.27.3953 10.1002/cncr.22831 10.1200/JCO.2004.05.017 10.1200/JCO.2008.17.1249 10.1159/000209334 10.1016/S0140-6736(02)08514-8 10.1038/sj.bjc.6601713 10.2165/00003495-199855030-00012 10.1093/jjco/hyi071 10.1200/JCO.1998.16.1.301 10.1007/s10147-005-0516-7 10.1038/bjc.1998.160 10.1007/s00432-007-0250-9 10.1093/annonc/mdg285 10.1007/s00280-005-0178-1 10.1093/oxfordjournals.annonc.a010800 10.1007/s00280-003-0613-0 10.1097/00001813-199708002-00004 10.1200/JCO.2007.13.1193 10.1200/JCO.2006.08.1620 10.1200/JCO.1998.16.9.2943 |
| ContentType | Journal Article |
| Copyright | Elsevier Inc. 2013 Elsevier Inc. Copyright © 2013 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Elsevier Inc. – notice: 2013 Elsevier Inc. – notice: Copyright © 2013 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
| DOI | 10.1016/j.clcc.2012.09.003 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1938-0674 |
| EndPage | 14 |
| ExternalDocumentID | 10_1016_j_clcc_2012_09_003 23102544 S1533002812001107 1_s2_0_S1533002812001107 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 5VS 6J9 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO ABBQC ABFNM ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEGXH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OC~ OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR CGR CUY CVF ECM EIF NPM AAYXX CITATION |
| ID | FETCH-LOGICAL-c455t-db36f9fbbd97d9a10419dc740dec4bb2e5a29829c66ef52578b57a39d5bb69563 |
| ISSN | 1533-0028 |
| IngestDate | Thu Sep 26 16:23:22 EDT 2024 Sat Sep 28 08:04:45 EDT 2024 Fri Feb 23 02:33:51 EST 2024 Tue Oct 15 22:57:11 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Raltitrexed Fluoropyrimidine-induced toxicity Chemotherapy S-1 |
| Language | English |
| License | Copyright © 2013 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c455t-db36f9fbbd97d9a10419dc740dec4bb2e5a29829c66ef52578b57a39d5bb69563 |
| OpenAccessLink | http://www.clinical-colorectal-cancer.com/article/S1533002812001107/pdf |
| PMID | 23102544 |
| PageCount | 7 |
| ParticipantIDs | crossref_primary_10_1016_j_clcc_2012_09_003 pubmed_primary_23102544 elsevier_sciencedirect_doi_10_1016_j_clcc_2012_09_003 elsevier_clinicalkeyesjournals_1_s2_0_S1533002812001107 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-03-01 |
| PublicationDateYYYYMMDD | 2013-03-01 |
| PublicationDate_xml | – month: 03 year: 2013 text: 2013-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical colorectal cancer |
| PublicationTitleAlternate | Clin Colorectal Cancer |
| PublicationYear | 2013 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Van den Brande, Schöffski, Schellens (bib46) 2003; 88 Gravalos, Garcia-Giron, Salud (bib60) 2005; 23 Feliu, Salud, Escudero (bib65) 2004; 90 Burger, Mannino (bib19) 1987; 114 Mizuno, Hokamura, Kimura (bib20) 1995; 59 Scheithauer, Kornek, Schuell (bib61) 2001; 12 bib36 Gunasekara, Faulds (bib51) 1998; 55 de Forni, Malet-Martino, Jaillais (bib6) 1992; 10 Van Cutsem, Peeters, Siena (bib78) 2007; 25 Feliu, Castañón, Salud (bib66) 2005; 93 Fuchs, Moore, Harker (bib69) 2003; 21 Kosmas, Kallistratos, Kopterides (bib5) 2008; 134 Muro, Boku, Shimada (bib43) 2010; 11 Saif, Tomita, Ledbetter (bib14) 2008; 6 Laudani, Gebbia, Leonardi (bib62) 2004; 24 Thirion, Michiels, Pignon (bib1) 2004; 22 Pazdur, Vincent (bib55) 1997 Jensen, Sørensen (bib17) 2006; 58 Miura, Shirasaka, Yamaue (bib45) 2012; 9 Carnaghi, Rimassa, Garassino (bib64) 2002; 13 Douillard, Hoff, Skillings (bib37) 2002; 20 Van Cutsem, Hoff, Blum (bib13) 2002; 13 Ng, Cunningham, Norman (bib8) 2005; 41 Park, Lim, Lee (bib44) 2011; 29 Muneoka, Shirai, Yokoyama (bib50) 2005; 10 Patel, Kloner, Ensley (bib24) 1987; 294 Patterson, Peters (bib26) 1966 Tsibiribi, Bui-Xuan, Bui-Xuan (bib23) 2006; 25 Fischer von Weikersthal, Schalhorn, Stauch (bib75) 2011; 47 Ashley, Sargent, Alberts (bib74) 2007; 110 Reigner, Verweij, Dirix (bib49) 1998; 4 Oostendorp, Stalmeier, Pasker-de Jong (bib70) 2010; 21 Südhoff, Enderle, Pahlke (bib18) 2004; 15 Yamamoto, Haruno, Yoshimura (bib32) 1984; 73 Guo, Harold, Saif (bib34) 2003; 52 Van Cutsem, Dirix, Van Laethem (bib71) 2005; 92 Cunningham, Humblet, Siena (bib72) 2004; 351 Robben, Pippas, Moore (bib16) 1993; 71 (bib2) 1998; 16 Yamada, Hamaguchi, Goto (bib48) 2003; 89 Matsubara, Kamiya, Imai (bib27) 1980; 30 Zalcberg (bib57) 1997; 8 Sobrero, Maurel, Fehrenbacher (bib73) 2008; 26 Haller, Rothenberg, Wong (bib76) 2008; 26 Labianca, Beretta, Clerici (bib9) 1982; 68 Peters, Noordhuis, Van Kuilenburg (bib47) 2003; 52 Jensen, Hasbak, Mortensen (bib12) 2010; 28 Akhtar, Salim, Bano (bib7) 1993; 50 Aparicio, Vicent, Maestu (bib67) 2003; 14 Maughan, James, Kerr (bib56) 2002; 359 Stewart, Pavlakis, Ward (bib29) 2010; 40 Jonker, O'Callaghan, Karapetis (bib77) 2007; 357 Jensen, Sørensen (bib22) 2012; 69 Wilson, Fitzgerald, Barnett (bib63) 2007; 25 Cassidy, Clarke, Díaz-Rubio (bib4) 2008; 26 Schöber, Papageorgiou, Harstrick (bib10) 1993; 72 Lembersky, Wieand, Petrelli (bib38) 2006; 24 Cocconi, Cunningham, Van Cutsem (bib54) 1998; 16 Bennouna, Saunders, Douillard (bib41) 2009; 76 Cianci, Morelli, Cannita (bib31) 2003; 88 Shaib, Lee, Saif (bib28) 2009; 23 Köhne, Thuss-Patience, Friedrich (bib59) 1998; 77 Alter, Herzum, Soufi (bib15) 2006; 4 Cerny, Hassan, Smith (bib30) 2009; 8 Chu, Eng, Abbruzzese (bib3) 2003; 2 Shirao, Hoff, Ohtsu (bib39) 2004; 22 Popov, Carrato, Sobrero (bib52) 2008; 44 Saltz, Cox, Blanke (bib68) 2000; 343 Arellano, Malet-Martino, Martino (bib25) 1998; 77 Nutting, Folkes (bib58) 1999; 11 Marsh, Catalano, Huang (bib35) 2002; 2 Yip, Karapetis, Strickland (bib33) 2003; 14 Saif, Shah, Shah (bib21) 2009; 8 Sellés, Castellano, Zomora (bib42) 2001; 18 Haller, Cassidy, Clarke (bib40) 2008; 24 Cunningham, Zalcberg, Rath (bib53) 1996; 7 Meydan, Kundak, Yavuzsen (bib11) 2005; 35 Saif (10.1016/j.clcc.2012.09.003_bib14) 2008; 6 Yamada (10.1016/j.clcc.2012.09.003_bib48) 2003; 89 Douillard (10.1016/j.clcc.2012.09.003_bib37) 2002; 20 Gunasekara (10.1016/j.clcc.2012.09.003_bib51) 1998; 55 Guo (10.1016/j.clcc.2012.09.003_bib34) 2003; 52 (10.1016/j.clcc.2012.09.003_bib2) 1998; 16 Van den Brande (10.1016/j.clcc.2012.09.003_bib46) 2003; 88 Shaib (10.1016/j.clcc.2012.09.003_bib28) 2009; 23 Cianci (10.1016/j.clcc.2012.09.003_bib31) 2003; 88 Jonker (10.1016/j.clcc.2012.09.003_bib77) 2007; 357 Feliu (10.1016/j.clcc.2012.09.003_bib66) 2005; 93 Burger (10.1016/j.clcc.2012.09.003_bib19) 1987; 114 Pazdur (10.1016/j.clcc.2012.09.003_bib55) 1997 Carnaghi (10.1016/j.clcc.2012.09.003_bib64) 2002; 13 Gravalos (10.1016/j.clcc.2012.09.003_bib60) 2005; 23 Cunningham (10.1016/j.clcc.2012.09.003_bib72) 2004; 351 Chu (10.1016/j.clcc.2012.09.003_bib3) 2003; 2 Park (10.1016/j.clcc.2012.09.003_bib44) 2011; 29 Akhtar (10.1016/j.clcc.2012.09.003_bib7) 1993; 50 Schöber (10.1016/j.clcc.2012.09.003_bib10) 1993; 72 Nutting (10.1016/j.clcc.2012.09.003_bib58) 1999; 11 Stewart (10.1016/j.clcc.2012.09.003_bib29) 2010; 40 Arellano (10.1016/j.clcc.2012.09.003_bib25) 1998; 77 Scheithauer (10.1016/j.clcc.2012.09.003_bib61) 2001; 12 Fuchs (10.1016/j.clcc.2012.09.003_bib69) 2003; 21 Cerny (10.1016/j.clcc.2012.09.003_bib30) 2009; 8 Sellés (10.1016/j.clcc.2012.09.003_bib42) 2001; 18 Meydan (10.1016/j.clcc.2012.09.003_bib11) 2005; 35 Jensen (10.1016/j.clcc.2012.09.003_bib22) 2012; 69 Popov (10.1016/j.clcc.2012.09.003_bib52) 2008; 44 Aparicio (10.1016/j.clcc.2012.09.003_bib67) 2003; 14 Yamamoto (10.1016/j.clcc.2012.09.003_bib32) 1984; 73 Köhne (10.1016/j.clcc.2012.09.003_bib59) 1998; 77 Jensen (10.1016/j.clcc.2012.09.003_bib12) 2010; 28 Lembersky (10.1016/j.clcc.2012.09.003_bib38) 2006; 24 Cassidy (10.1016/j.clcc.2012.09.003_bib4) 2008; 26 Zalcberg (10.1016/j.clcc.2012.09.003_bib57) 1997; 8 Muneoka (10.1016/j.clcc.2012.09.003_bib50) 2005; 10 Ashley (10.1016/j.clcc.2012.09.003_bib74) 2007; 110 Laudani (10.1016/j.clcc.2012.09.003_bib62) 2004; 24 Van Cutsem (10.1016/j.clcc.2012.09.003_bib71) 2005; 92 Robben (10.1016/j.clcc.2012.09.003_bib16) 1993; 71 Patel (10.1016/j.clcc.2012.09.003_bib24) 1987; 294 Muro (10.1016/j.clcc.2012.09.003_bib43) 2010; 11 Fischer von Weikersthal (10.1016/j.clcc.2012.09.003_bib75) 2011; 47 Jensen (10.1016/j.clcc.2012.09.003_bib17) 2006; 58 Van Cutsem (10.1016/j.clcc.2012.09.003_bib78) 2007; 25 Saif (10.1016/j.clcc.2012.09.003_bib21) 2009; 8 Patterson (10.1016/j.clcc.2012.09.003_bib26) 1966 Bennouna (10.1016/j.clcc.2012.09.003_bib41) 2009; 76 Ng (10.1016/j.clcc.2012.09.003_bib8) 2005; 41 Kosmas (10.1016/j.clcc.2012.09.003_bib5) 2008; 134 Feliu (10.1016/j.clcc.2012.09.003_bib65) 2004; 90 Miura (10.1016/j.clcc.2012.09.003_bib45) 2012; 9 Saltz (10.1016/j.clcc.2012.09.003_bib68) 2000; 343 Mizuno (10.1016/j.clcc.2012.09.003_bib20) 1995; 59 Marsh (10.1016/j.clcc.2012.09.003_bib35) 2002; 2 Haller (10.1016/j.clcc.2012.09.003_bib40) 2008; 24 Cunningham (10.1016/j.clcc.2012.09.003_bib53) 1996; 7 Oostendorp (10.1016/j.clcc.2012.09.003_bib70) 2010; 21 Van Cutsem (10.1016/j.clcc.2012.09.003_bib13) 2002; 13 Peters (10.1016/j.clcc.2012.09.003_bib47) 2003; 52 Tsibiribi (10.1016/j.clcc.2012.09.003_bib23) 2006; 25 Yip (10.1016/j.clcc.2012.09.003_bib33) 2003; 14 Reigner (10.1016/j.clcc.2012.09.003_bib49) 1998; 4 Sobrero (10.1016/j.clcc.2012.09.003_bib73) 2008; 26 Thirion (10.1016/j.clcc.2012.09.003_bib1) 2004; 22 Südhoff (10.1016/j.clcc.2012.09.003_bib18) 2004; 15 Cocconi (10.1016/j.clcc.2012.09.003_bib54) 1998; 16 de Forni (10.1016/j.clcc.2012.09.003_bib6) 1992; 10 Maughan (10.1016/j.clcc.2012.09.003_bib56) 2002; 359 Labianca (10.1016/j.clcc.2012.09.003_bib9) 1982; 68 Wilson (10.1016/j.clcc.2012.09.003_bib63) 2007; 25 Shirao (10.1016/j.clcc.2012.09.003_bib39) 2004; 22 Haller (10.1016/j.clcc.2012.09.003_bib76) 2008; 26 Alter (10.1016/j.clcc.2012.09.003_bib15) 2006; 4 Matsubara (10.1016/j.clcc.2012.09.003_bib27) 1980; 30 |
| References_xml | – volume: 114 start-page: 433 year: 1987 end-page: 436 ident: bib19 article-title: 5-Fluorouracil-induced coronary vasospasm publication-title: Am Heart J contributor: fullname: Mannino – volume: 93 start-page: 1230 year: 2005 end-page: 1235 ident: bib66 article-title: Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer publication-title: Br J Cancer contributor: fullname: Salud – volume: 8 start-page: 191 year: 2009 end-page: 202 ident: bib21 article-title: Fluoropyrimidine-associated cardiotoxicity: revisited publication-title: Expert Opin Drug Saf contributor: fullname: Shah – volume: 88 start-page: 648 year: 2003 end-page: 653 ident: bib46 article-title: EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer publication-title: Br J Cancer contributor: fullname: Schellens – volume: 11 start-page: 66 year: 1999 ident: bib58 article-title: The use of raltitrexed (Tomudex) in a patient with 5-FU induced myocardial ischaemia publication-title: J Clin Oncol contributor: fullname: Folkes – volume: 9 start-page: 273 year: 2012 end-page: 286 ident: bib45 article-title: S-1 as a core anticancer fluoropyrimidine agent publication-title: Expert Opin Drug Deliv contributor: fullname: Yamaue – volume: 4 start-page: 941 year: 1998 end-page: 948 ident: bib49 article-title: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients publication-title: Clin Cancer Res contributor: fullname: Dirix – volume: 14 start-page: 1121 year: 2003 end-page: 1125 ident: bib67 article-title: Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer publication-title: Ann Oncol contributor: fullname: Maestu – volume: 26 start-page: 2311 year: 2008 end-page: 2319 ident: bib73 article-title: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer publication-title: J Clin Oncol contributor: fullname: Fehrenbacher – volume: 73 start-page: 212 year: 1984 end-page: 214 ident: bib32 article-title: Effect of coadministration of uracil on the toxicity of tegafur publication-title: J Pharm Sci contributor: fullname: Yoshimura – volume: 10 start-page: 441 year: 2005 end-page: 443 ident: bib50 article-title: 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine publication-title: Int J Clin Oncol contributor: fullname: Yokoyama – volume: 24 start-page: 1139 year: 2004 end-page: 1142 ident: bib62 article-title: Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma publication-title: Anticancer Res contributor: fullname: Leonardi – volume: 20 start-page: 3605 year: 2002 end-page: 3616 ident: bib37 article-title: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer publication-title: J Clin Oncol contributor: fullname: Skillings – volume: 8 start-page: 55 year: 2009 end-page: 58 ident: bib30 article-title: Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen publication-title: Clin Colorectal Cancer contributor: fullname: Smith – volume: 14 start-page: 864 year: 2003 end-page: 866 ident: bib33 article-title: A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies publication-title: Ann Oncol contributor: fullname: Strickland – volume: 44 start-page: 2204 year: 2008 end-page: 2211 ident: bib52 article-title: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) publication-title: Eur J Cancer contributor: fullname: Sobrero – volume: 52 start-page: 1 year: 2003 end-page: 12 ident: bib47 article-title: Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors publication-title: Cancer Chemother Pharmacol contributor: fullname: Van Kuilenburg – volume: 26 start-page: 2006 year: 2008 end-page: 2012 ident: bib4 article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer publication-title: J Clin Oncol contributor: fullname: Díaz-Rubio – volume: 23 year: 2005 ident: bib60 article-title: TOMOX compared to FOLFOX 4 as first-line treatment in patients with advanced colorectal cancer (ACRC): results of a multicenter randomised phase II trial publication-title: J Clin Oncol contributor: fullname: Salud – volume: 30 start-page: 871 year: 1980 end-page: 879 ident: bib27 article-title: Cardiotoxic effects of 5-fluorouracil in the guinea pig publication-title: Jpn J Pharmacol contributor: fullname: Imai – volume: 69 start-page: 57 year: 2012 end-page: 64 ident: bib22 article-title: 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity publication-title: Cancer Chemother Pharmacol contributor: fullname: Sørensen – start-page: 387 year: 1966 end-page: 458 ident: bib26 article-title: Monofluoro aliphatic compounds publication-title: Handbook of Experimental Pharmacology contributor: fullname: Peters – volume: 59 start-page: 303 year: 1995 end-page: 307 ident: bib20 article-title: A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction publication-title: Jpn Circ J contributor: fullname: Kimura – volume: 58 start-page: 487 year: 2006 end-page: 493 ident: bib17 article-title: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine publication-title: Cancer Chemother Pharmacol contributor: fullname: Sørensen – volume: 21 start-page: 749 year: 2010 end-page: 758 ident: bib70 article-title: Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer publication-title: Anticancer Drugs contributor: fullname: Pasker-de Jong – volume: 351 start-page: 337 year: 2004 end-page: 345 ident: bib72 article-title: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer publication-title: N Engl J Med contributor: fullname: Siena – volume: 18 start-page: 2 year: 2001 ident: bib42 article-title: Vasospasm after chemotherapy with 5-fluorouracil [in Spanish] publication-title: An Med Int contributor: fullname: Zomora – volume: 343 start-page: 905 year: 2000 end-page: 914 ident: bib68 article-title: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med contributor: fullname: Blanke – volume: 2 start-page: 1 year: 2003 end-page: 28 ident: bib3 article-title: Efficacy and safety of capecitabine for colorectal cancer publication-title: Am J Oncol Rev contributor: fullname: Abbruzzese – volume: 25 start-page: 1658 year: 2007 end-page: 1664 ident: bib78 article-title: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer publication-title: J Clin Oncol contributor: fullname: Siena – volume: 13 start-page: 1424 year: 2002 end-page: 1429 ident: bib64 article-title: Irinotecan and raltitrexed: an active combination in advanced colorectal cancer publication-title: Ann Oncol contributor: fullname: Garassino – volume: 25 start-page: 305 year: 2006 end-page: 309 ident: bib23 article-title: Cardiac lesions induced by 5-fluorouracil in the rabbit publication-title: Hum Exp Toxicol contributor: fullname: Bui-Xuan – volume: 72 start-page: 2242 year: 1993 end-page: 2247 ident: bib10 article-title: Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer publication-title: Cancer contributor: fullname: Harstrick – volume: 90 start-page: 1502 year: 2004 end-page: 1507 ident: bib65 article-title: Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study publication-title: Br J Cancer contributor: fullname: Escudero – volume: 21 start-page: 807 year: 2003 end-page: 814 ident: bib69 article-title: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer publication-title: J Clin Oncol contributor: fullname: Harker – volume: 110 start-page: 670 year: 2007 end-page: 677 ident: bib74 article-title: Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer publication-title: Cancer contributor: fullname: Alberts – volume: 29 year: 2011 ident: bib44 article-title: A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer publication-title: J Clin Oncol contributor: fullname: Lee – year: 1997 ident: bib55 article-title: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5- FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized multicenter, North American trial publication-title: Proc Am Soc Clin Oncol contributor: fullname: Vincent – volume: 41 start-page: 1542 year: 2005 end-page: 1546 ident: bib8 article-title: The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) publication-title: Eur J Cancer contributor: fullname: Norman – volume: 92 start-page: 1055 year: 2005 end-page: 1062 ident: bib71 article-title: Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study publication-title: Br J Cancer contributor: fullname: Van Laethem – volume: 77 start-page: 79 year: 1998 end-page: 86 ident: bib25 article-title: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate publication-title: Br J Cancer contributor: fullname: Martino – volume: 357 start-page: 2040 year: 2007 end-page: 2048 ident: bib77 article-title: Cetuximab for the treatment of colorectal cancer publication-title: N Engl J Med contributor: fullname: Karapetis – volume: 16 start-page: 301 year: 1998 end-page: 308 ident: bib2 article-title: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer publication-title: J Clin Oncol – volume: 25 start-page: 711 year: 2007 end-page: 714 ident: bib63 article-title: Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience publication-title: Cancer Invest contributor: fullname: Barnett – volume: 40 start-page: 303 year: 2010 end-page: 307 ident: bib29 article-title: Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina publication-title: Intern Med J contributor: fullname: Ward – volume: 8 start-page: S17 year: 1997 end-page: S22 ident: bib57 article-title: Overview of the tolerability of ‘Tomudex’ (raltitrexed): collective clinical experience in advanced colorectal cancer publication-title: Anti Cancer Drugs contributor: fullname: Zalcberg – volume: 22 start-page: 3466 year: 2004 end-page: 3474 ident: bib39 article-title: Comparison of the efficacy, toxicity and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV publication-title: J Clin Oncol contributor: fullname: Ohtsu – volume: 10 start-page: 1795 year: 1992 end-page: 1801 ident: bib6 article-title: Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study publication-title: J Clin Oncol contributor: fullname: Jaillais – volume: 52 start-page: 79 year: 2003 end-page: 85 ident: bib34 article-title: Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule publication-title: Cancer Chemother Pharmacol contributor: fullname: Saif – ident: bib36 article-title: Adverse events reported to the FDA – volume: 24 start-page: 2059 year: 2006 end-page: 2064 ident: bib38 article-title: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project Protocol C-06 publication-title: J Clin Oncol contributor: fullname: Petrelli – volume: 16 start-page: 2943 year: 1998 end-page: 2952 ident: bib54 article-title: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer publication-title: J Clin Oncol contributor: fullname: Van Cutsem – volume: 6 start-page: 41 year: 2008 end-page: 48 ident: bib14 article-title: Capecitabine-related cardiotoxicity: recognition and management publication-title: J Support Oncol contributor: fullname: Ledbetter – volume: 89 start-page: 816 year: 2003 end-page: 820 ident: bib48 article-title: Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil publication-title: Br J Cancer contributor: fullname: Goto – volume: 11 start-page: 853 year: 2010 end-page: 860 ident: bib43 article-title: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) publication-title: Lancet Oncol contributor: fullname: Shimada – volume: 134 start-page: 75 year: 2008 end-page: 82 ident: bib5 article-title: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study publication-title: J Cancer Res Clin Oncol contributor: fullname: Kopterides – volume: 13 start-page: 484 year: 2002 end-page: 485 ident: bib13 article-title: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil publication-title: Ann Oncol contributor: fullname: Blum – volume: 4 start-page: 1 year: 2006 end-page: 5 ident: bib15 article-title: Cardiotoxicity of 5-fluorouracil publication-title: Cardiovasc Hematol Agents Med Chem contributor: fullname: Soufi – volume: 15 start-page: 661 year: 2004 end-page: 664 ident: bib18 article-title: 5-Fluorouracil induces arterial vasocontractions publication-title: Ann Oncol contributor: fullname: Pahlke – volume: 359 start-page: 1555 year: 2002 end-page: 1563 ident: bib56 article-title: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial publication-title: Lancet contributor: fullname: Kerr – volume: 2 start-page: 43 year: 2002 end-page: 50 ident: bib35 article-title: Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer publication-title: Clin Colorectal Cancer contributor: fullname: Huang – volume: 71 start-page: 493 year: 1993 end-page: 499 ident: bib16 article-title: The syndrome of 5-fluorouracil cardiotoxicity publication-title: Cancer contributor: fullname: Moore – volume: 55 start-page: 423 year: 1998 end-page: 435 ident: bib51 article-title: Raltitrexed publication-title: Drugs contributor: fullname: Faulds – volume: 23 start-page: 821 year: 2009 end-page: 826 ident: bib28 article-title: Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity publication-title: In Vivo contributor: fullname: Saif – volume: 77 start-page: 973 year: 1998 end-page: 977 ident: bib59 article-title: Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-FU publication-title: Br J Cancer contributor: fullname: Friedrich – volume: 88 start-page: 1507 year: 2003 end-page: 1509 ident: bib31 article-title: Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity publication-title: Br J Cancer contributor: fullname: Cannita – volume: 12 start-page: 709 year: 2001 end-page: 714 ident: bib61 article-title: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy publication-title: Ann Oncol contributor: fullname: Schuell – volume: 47 start-page: 206 year: 2011 end-page: 214 ident: bib75 article-title: Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer publication-title: Eur J Cancer contributor: fullname: Stauch – volume: 35 start-page: 265 year: 2005 end-page: 270 ident: bib11 article-title: Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up publication-title: Jpn J Clin Oncol contributor: fullname: Yavuzsen – volume: 28 start-page: 5280 year: 2010 end-page: 5286 ident: bib12 article-title: Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle publication-title: J Clin Oncol contributor: fullname: Mortensen – volume: 50 start-page: 441 year: 1993 end-page: 444 ident: bib7 article-title: Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study publication-title: Oncology contributor: fullname: Bano – volume: 22 start-page: 3766 year: 2004 end-page: 3775 ident: bib1 article-title: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: un updated analysis [published erratum appears in publication-title: J Clin Oncol contributor: fullname: Pignon – volume: 294 start-page: 238 year: 1987 end-page: 243 ident: bib24 article-title: 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators publication-title: Am J Med Sci contributor: fullname: Ensley – volume: 24 start-page: 2059 year: 2008 end-page: 2064 ident: bib40 article-title: Potential regional differences for the tolerability profiles of fluoropyrimidines publication-title: J Clin Oncol contributor: fullname: Clarke – volume: 68 start-page: 505 year: 1982 end-page: 510 ident: bib9 article-title: Cardiac toxicity of 5-fluorouracil: a study on 1083 patients publication-title: Tumori contributor: fullname: Clerici – volume: 7 start-page: 961 year: 1996 end-page: 965 ident: bib53 article-title: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer publication-title: Ann Oncol contributor: fullname: Rath – volume: 26 start-page: 4544 year: 2008 end-page: 4550 ident: bib76 article-title: Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma publication-title: J Clin Oncol contributor: fullname: Wong – volume: 76 start-page: 301 year: 2009 end-page: 310 ident: bib41 article-title: The role of UFT in metastatic colorectal cancer publication-title: Oncology contributor: fullname: Douillard – volume: 52 start-page: 1 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib47 article-title: Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-003-0617-9 contributor: fullname: Peters – volume: 41 start-page: 1542 year: 2005 ident: 10.1016/j.clcc.2012.09.003_bib8 article-title: The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2005.03.027 contributor: fullname: Ng – volume: 4 start-page: 941 year: 1998 ident: 10.1016/j.clcc.2012.09.003_bib49 article-title: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients publication-title: Clin Cancer Res contributor: fullname: Reigner – volume: 15 start-page: 661 year: 2004 ident: 10.1016/j.clcc.2012.09.003_bib18 article-title: 5-Fluorouracil induces arterial vasocontractions publication-title: Ann Oncol doi: 10.1093/annonc/mdh150 contributor: fullname: Südhoff – volume: 88 start-page: 648 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib46 article-title: EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600781 contributor: fullname: Van den Brande – volume: 88 start-page: 1507 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib31 article-title: Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600967 contributor: fullname: Cianci – volume: 13 start-page: 484 year: 2002 ident: 10.1016/j.clcc.2012.09.003_bib13 article-title: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil publication-title: Ann Oncol doi: 10.1093/annonc/mdf108 contributor: fullname: Van Cutsem – volume: 10 start-page: 1795 year: 1992 ident: 10.1016/j.clcc.2012.09.003_bib6 article-title: Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study publication-title: J Clin Oncol doi: 10.1200/JCO.1992.10.11.1795 contributor: fullname: de Forni – volume: 4 start-page: 1 year: 2006 ident: 10.1016/j.clcc.2012.09.003_bib15 article-title: Cardiotoxicity of 5-fluorouracil publication-title: Cardiovasc Hematol Agents Med Chem doi: 10.2174/187152506775268785 contributor: fullname: Alter – volume: 25 start-page: 305 year: 2006 ident: 10.1016/j.clcc.2012.09.003_bib23 article-title: Cardiac lesions induced by 5-fluorouracil in the rabbit publication-title: Hum Exp Toxicol doi: 10.1191/0960327106ht628oa contributor: fullname: Tsibiribi – volume: 11 start-page: 853 year: 2010 ident: 10.1016/j.clcc.2012.09.003_bib43 article-title: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70181-9 contributor: fullname: Muro – volume: 72 start-page: 2242 year: 1993 ident: 10.1016/j.clcc.2012.09.003_bib10 article-title: Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer publication-title: Cancer doi: 10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E contributor: fullname: Schöber – volume: 6 start-page: 41 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib14 article-title: Capecitabine-related cardiotoxicity: recognition and management publication-title: J Support Oncol contributor: fullname: Saif – volume: 77 start-page: 79 year: 1998 ident: 10.1016/j.clcc.2012.09.003_bib25 article-title: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate publication-title: Br J Cancer doi: 10.1038/bjc.1998.12 contributor: fullname: Arellano – volume: 14 start-page: 864 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib33 article-title: A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies publication-title: Ann Oncol doi: 10.1093/annonc/mdg254 contributor: fullname: Yip – volume: 50 start-page: 441 year: 1993 ident: 10.1016/j.clcc.2012.09.003_bib7 article-title: Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study publication-title: Oncology doi: 10.1159/000227226 contributor: fullname: Akhtar – volume: 71 start-page: 493 year: 1993 ident: 10.1016/j.clcc.2012.09.003_bib16 article-title: The syndrome of 5-fluorouracil cardiotoxicity publication-title: Cancer doi: 10.1002/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C contributor: fullname: Robben – volume: 23 start-page: 821 year: 2009 ident: 10.1016/j.clcc.2012.09.003_bib28 article-title: Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity publication-title: In Vivo contributor: fullname: Shaib – year: 1997 ident: 10.1016/j.clcc.2012.09.003_bib55 article-title: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5- FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized multicenter, North American trial publication-title: Proc Am Soc Clin Oncol contributor: fullname: Pazdur – volume: 44 start-page: 2204 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib52 article-title: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.07.002 contributor: fullname: Popov – volume: 12 start-page: 709 year: 2001 ident: 10.1016/j.clcc.2012.09.003_bib61 article-title: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy publication-title: Ann Oncol doi: 10.1023/A:1011194712661 contributor: fullname: Scheithauer – volume: 343 start-page: 905 year: 2000 ident: 10.1016/j.clcc.2012.09.003_bib68 article-title: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJM200009283431302 contributor: fullname: Saltz – volume: 47 start-page: 206 year: 2011 ident: 10.1016/j.clcc.2012.09.003_bib75 article-title: Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.09.022 contributor: fullname: Fischer von Weikersthal – volume: 294 start-page: 238 year: 1987 ident: 10.1016/j.clcc.2012.09.003_bib24 article-title: 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators publication-title: Am J Med Sci doi: 10.1097/00000441-198710000-00004 contributor: fullname: Patel – volume: 69 start-page: 57 year: 2012 ident: 10.1016/j.clcc.2012.09.003_bib22 article-title: 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-011-1669-x contributor: fullname: Jensen – volume: 18 start-page: 2 year: 2001 ident: 10.1016/j.clcc.2012.09.003_bib42 article-title: Vasospasm after chemotherapy with 5-fluorouracil [in Spanish] publication-title: An Med Int contributor: fullname: Sellés – volume: 59 start-page: 303 year: 1995 ident: 10.1016/j.clcc.2012.09.003_bib20 article-title: A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction publication-title: Jpn Circ J doi: 10.1253/jcj.59.303 contributor: fullname: Mizuno – volume: 114 start-page: 433 year: 1987 ident: 10.1016/j.clcc.2012.09.003_bib19 article-title: 5-Fluorouracil-induced coronary vasospasm publication-title: Am Heart J doi: 10.1016/0002-8703(87)90517-5 contributor: fullname: Burger – volume: 357 start-page: 2040 year: 2007 ident: 10.1016/j.clcc.2012.09.003_bib77 article-title: Cetuximab for the treatment of colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa071834 contributor: fullname: Jonker – volume: 73 start-page: 212 year: 1984 ident: 10.1016/j.clcc.2012.09.003_bib32 article-title: Effect of coadministration of uracil on the toxicity of tegafur publication-title: J Pharm Sci doi: 10.1002/jps.2600730217 contributor: fullname: Yamamoto – volume: 13 start-page: 1424 year: 2002 ident: 10.1016/j.clcc.2012.09.003_bib64 article-title: Irinotecan and raltitrexed: an active combination in advanced colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdf229 contributor: fullname: Carnaghi – volume: 40 start-page: 303 year: 2010 ident: 10.1016/j.clcc.2012.09.003_bib29 article-title: Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina publication-title: Intern Med J doi: 10.1111/j.1445-5994.2009.02144.x contributor: fullname: Stewart – volume: 21 start-page: 749 year: 2010 ident: 10.1016/j.clcc.2012.09.003_bib70 article-title: Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer publication-title: Anticancer Drugs doi: 10.1097/CAD.0b013e32833c57cf contributor: fullname: Oostendorp – volume: 8 start-page: 191 year: 2009 ident: 10.1016/j.clcc.2012.09.003_bib21 article-title: Fluoropyrimidine-associated cardiotoxicity: revisited publication-title: Expert Opin Drug Saf doi: 10.1517/14740330902733961 contributor: fullname: Saif – volume: 93 start-page: 1230 year: 2005 ident: 10.1016/j.clcc.2012.09.003_bib66 article-title: Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602860 contributor: fullname: Feliu – volume: 21 start-page: 807 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib69 article-title: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2003.08.058 contributor: fullname: Fuchs – volume: 26 start-page: 2006 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib4 article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.9898 contributor: fullname: Cassidy – volume: 30 start-page: 871 year: 1980 ident: 10.1016/j.clcc.2012.09.003_bib27 article-title: Cardiotoxic effects of 5-fluorouracil in the guinea pig publication-title: Jpn J Pharmacol doi: 10.1254/jjp.30.871 contributor: fullname: Matsubara – volume: 68 start-page: 505 year: 1982 ident: 10.1016/j.clcc.2012.09.003_bib9 article-title: Cardiac toxicity of 5-fluorouracil: a study on 1083 patients publication-title: Tumori doi: 10.1177/030089168206800609 contributor: fullname: Labianca – volume: 11 start-page: 66 year: 1999 ident: 10.1016/j.clcc.2012.09.003_bib58 article-title: The use of raltitrexed (Tomudex) in a patient with 5-FU induced myocardial ischaemia publication-title: J Clin Oncol contributor: fullname: Nutting – volume: 92 start-page: 1055 year: 2005 ident: 10.1016/j.clcc.2012.09.003_bib71 article-title: Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602462 contributor: fullname: Van Cutsem – volume: 29 issue: Suppl year: 2011 ident: 10.1016/j.clcc.2012.09.003_bib44 article-title: A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer publication-title: J Clin Oncol doi: 10.1200/jco.2011.29.15_suppl.3524 contributor: fullname: Park – volume: 2 start-page: 43 year: 2002 ident: 10.1016/j.clcc.2012.09.003_bib35 article-title: Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer publication-title: Clin Colorectal Cancer doi: 10.3816/CCC.2002.n.010 contributor: fullname: Marsh – volume: 25 start-page: 711 year: 2007 ident: 10.1016/j.clcc.2012.09.003_bib63 article-title: Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience publication-title: Cancer Invest doi: 10.1080/07357900701518388 contributor: fullname: Wilson – start-page: 387 year: 1966 ident: 10.1016/j.clcc.2012.09.003_bib26 article-title: Monofluoro aliphatic compounds contributor: fullname: Patterson – volume: 89 start-page: 816 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib48 article-title: Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601224 contributor: fullname: Yamada – volume: 20 start-page: 3605 year: 2002 ident: 10.1016/j.clcc.2012.09.003_bib37 article-title: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2002.04.123 contributor: fullname: Douillard – volume: 8 start-page: 55 year: 2009 ident: 10.1016/j.clcc.2012.09.003_bib30 article-title: Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen publication-title: Clin Colorectal Cancer doi: 10.3816/CCC.2009.n.009 contributor: fullname: Cerny – volume: 351 start-page: 337 year: 2004 ident: 10.1016/j.clcc.2012.09.003_bib72 article-title: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa033025 contributor: fullname: Cunningham – volume: 9 start-page: 273 year: 2012 ident: 10.1016/j.clcc.2012.09.003_bib45 article-title: S-1 as a core anticancer fluoropyrimidine agent publication-title: Expert Opin Drug Deliv doi: 10.1517/17425247.2012.652945 contributor: fullname: Miura – volume: 24 start-page: 2059 year: 2006 ident: 10.1016/j.clcc.2012.09.003_bib38 article-title: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project Protocol C-06 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.7498 contributor: fullname: Lembersky – volume: 28 start-page: 5280 year: 2010 ident: 10.1016/j.clcc.2012.09.003_bib12 article-title: Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.3953 contributor: fullname: Jensen – volume: 110 start-page: 670 year: 2007 ident: 10.1016/j.clcc.2012.09.003_bib74 article-title: Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer publication-title: Cancer doi: 10.1002/cncr.22831 contributor: fullname: Ashley – volume: 22 start-page: 3466 year: 2004 ident: 10.1016/j.clcc.2012.09.003_bib39 article-title: Comparison of the efficacy, toxicity and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV publication-title: J Clin Oncol doi: 10.1200/JCO.2004.05.017 contributor: fullname: Shirao – volume: 2 start-page: 1 issue: suppl 3 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib3 article-title: Efficacy and safety of capecitabine for colorectal cancer publication-title: Am J Oncol Rev contributor: fullname: Chu – volume: 23 issue: June 1 Supplement year: 2005 ident: 10.1016/j.clcc.2012.09.003_bib60 article-title: TOMOX compared to FOLFOX 4 as first-line treatment in patients with advanced colorectal cancer (ACRC): results of a multicenter randomised phase II trial publication-title: J Clin Oncol contributor: fullname: Gravalos – volume: 26 start-page: 4544 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib76 article-title: Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.1249 contributor: fullname: Haller – volume: 76 start-page: 301 year: 2009 ident: 10.1016/j.clcc.2012.09.003_bib41 article-title: The role of UFT in metastatic colorectal cancer publication-title: Oncology doi: 10.1159/000209334 contributor: fullname: Bennouna – volume: 359 start-page: 1555 year: 2002 ident: 10.1016/j.clcc.2012.09.003_bib56 article-title: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08514-8 contributor: fullname: Maughan – volume: 90 start-page: 1502 year: 2004 ident: 10.1016/j.clcc.2012.09.003_bib65 article-title: Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601713 contributor: fullname: Feliu – volume: 55 start-page: 423 year: 1998 ident: 10.1016/j.clcc.2012.09.003_bib51 article-title: Raltitrexed publication-title: Drugs doi: 10.2165/00003495-199855030-00012 contributor: fullname: Gunasekara – volume: 35 start-page: 265 year: 2005 ident: 10.1016/j.clcc.2012.09.003_bib11 article-title: Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyi071 contributor: fullname: Meydan – volume: 16 start-page: 301 year: 1998 ident: 10.1016/j.clcc.2012.09.003_bib2 article-title: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.1.301 – volume: 10 start-page: 441 year: 2005 ident: 10.1016/j.clcc.2012.09.003_bib50 article-title: 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine publication-title: Int J Clin Oncol doi: 10.1007/s10147-005-0516-7 contributor: fullname: Muneoka – volume: 77 start-page: 973 year: 1998 ident: 10.1016/j.clcc.2012.09.003_bib59 article-title: Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-FU publication-title: Br J Cancer doi: 10.1038/bjc.1998.160 contributor: fullname: Köhne – volume: 134 start-page: 75 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib5 article-title: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-007-0250-9 contributor: fullname: Kosmas – volume: 14 start-page: 1121 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib67 article-title: Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdg285 contributor: fullname: Aparicio – volume: 58 start-page: 487 year: 2006 ident: 10.1016/j.clcc.2012.09.003_bib17 article-title: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-005-0178-1 contributor: fullname: Jensen – volume: 24 start-page: 2059 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib40 article-title: Potential regional differences for the tolerability profiles of fluoropyrimidines publication-title: J Clin Oncol contributor: fullname: Haller – volume: 24 start-page: 1139 year: 2004 ident: 10.1016/j.clcc.2012.09.003_bib62 article-title: Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma publication-title: Anticancer Res contributor: fullname: Laudani – volume: 7 start-page: 961 year: 1996 ident: 10.1016/j.clcc.2012.09.003_bib53 article-title: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a010800 contributor: fullname: Cunningham – volume: 22 start-page: 3766 year: 2004 ident: 10.1016/j.clcc.2012.09.003_bib1 article-title: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: un updated analysis [published erratum appears in J Clin Oncol 2005;23:1377-8] publication-title: J Clin Oncol contributor: fullname: Thirion – volume: 52 start-page: 79 year: 2003 ident: 10.1016/j.clcc.2012.09.003_bib34 article-title: Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-003-0613-0 contributor: fullname: Guo – volume: 8 start-page: S17 issue: Suppl 2 year: 1997 ident: 10.1016/j.clcc.2012.09.003_bib57 article-title: Overview of the tolerability of ‘Tomudex’ (raltitrexed): collective clinical experience in advanced colorectal cancer publication-title: Anti Cancer Drugs doi: 10.1097/00001813-199708002-00004 contributor: fullname: Zalcberg – volume: 26 start-page: 2311 year: 2008 ident: 10.1016/j.clcc.2012.09.003_bib73 article-title: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.1193 contributor: fullname: Sobrero – volume: 25 start-page: 1658 year: 2007 ident: 10.1016/j.clcc.2012.09.003_bib78 article-title: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.1620 contributor: fullname: Van Cutsem – volume: 16 start-page: 2943 year: 1998 ident: 10.1016/j.clcc.2012.09.003_bib54 article-title: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.9.2943 contributor: fullname: Cocconi |
| SSID | ssj0026311 |
| Score | 2.233987 |
| SecondaryResourceType | review_article |
| Snippet | Abstract Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common... Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but... |
| SourceID | crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 8 |
| SubjectTerms | Animals Antimetabolites, Antineoplastic - adverse effects Capecitabine Cardiovascular Agents - therapeutic use Chemotherapy Colorectal Neoplasms - drug therapy Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Fluoropyrimidine-induced toxicity Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Gastroenterology and Hepatology Heart Diseases - chemically induced Heart Diseases - prevention & control Hematology, Oncology and Palliative Medicine Humans Raltitrexed S-1 |
| Title | Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced Cardiotoxicity |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1533002812001107 https://dx.doi.org/10.1016/j.clcc.2012.09.003 https://www.ncbi.nlm.nih.gov/pubmed/23102544 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6lRUJcEG9SHtoDt8oo9vqRPVYmbQ8UJBoE4mLtK5LbKI6SGNFb_wP_kF_CjHe9dgjiJXGJoo3jXe18np0ZfzNDyItYcJGyNAxCplkQa6kCyVMdJCJFAzzjqnmje3qevfk4fjWJJ4NB25mxG_uvkoYxkDVmzv6FtP1NYQC-g8zhE6QOn38k96O5C_F9NodTzyJ_u_Sc8RzUHao5jBqgyFdYpr9sEt0-YFA2afkP7HheVyuYU6hyHiBxPRfYrX4jwJs2ATb9QPJA3jBaN9WXEn7aekmct1mXqptSNVN68xm0nXEc0pO61FUXCZ9vVtXSYdVnE-WuIdhZeekB-RqzzoyyIYaT-qofx8CeEqwfx_AJNlv8T7RGA_QL7XFlxzjoaDhk4y0lHu2A1Wrkce9ot-mqO4eGjV9cvFRzhUUtMTqMRUxZd0R64uI5LgjXE0ZNtb1sj9yIQMWhhv2UvPOufspCV6nXLt-la1lm4Y_z_MYk6tk70zvktnNU6JFF2F0yMIt75OaZo2LcJ1c9oFEPNOqARssF7YBGLdBoCzSKQKPJt-uvWxCj1Yr-DGJ0G2IPyPvjyTQ_DVwfj0DFSbIJtGTpjM-k1DzTXISjOORaZfFIGxVLGZlERHwccZWmZobVeccyyQTjOpEyBf-dPST7i2phHhNqIhUpxvSMCRlrDbaqFtkYLuGaK_CNh-Sw3cpiacu1FC2P8aLAjS9w44sRx6K4Q5K1u120ichwdJq1e57XRVis4eJiR-xDkvh_OlPVmqAFgOqXMz6yQvWrQ_8KywQe_OMdn5Bb3dP0lOxvVrV5RvbWun7eQPI75N_Afg |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alternative+Treatment+Options+in+Colorectal+Cancer+Patients+With+5%E2%80%93Fluorouracil-+or+Capecitabine-Induced+Cardiotoxicity&rft.jtitle=Clinical+colorectal+cancer&rft.au=Deboever%2C+Guido&rft.au=Hiltrop%2C+Nick&rft.au=Cool%2C+Mike&rft.au=Lambrecht%2C+Guy&rft.date=2013-03-01&rft.pub=Elsevier+Inc&rft.issn=1533-0028&rft.eissn=1938-0674&rft.volume=12&rft.issue=1&rft.spage=8&rft.epage=14&rft_id=info:doi/10.1016%2Fj.clcc.2012.09.003&rft.externalDocID=S1533002812001107 |
| thumbnail_m | http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15330028%2FS1533002813X00027%2Fcov150h.gif |